| Species |
Human |
| Protein Construction |
HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer [Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVGAVGVGK peptide]
Accession # AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVGAVGVGK |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer, His & Avi, Human captured on CM5 Chip via AntiHis Antibody can bind HLAA*11:01&B2M&KRAS G12V (VVGAVGVGK) TCR. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
50.2 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 56-65 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |
| Synonyms |
MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
